Devyser Diagnostics AB (publ)
Interim report January - June 2026

Q2

Temporarily weaker sales, but underlying demand remains strong

Quarter from April to June 2026

- Net sales amounted to SEK 60.2 million (67.4), corresponding to a 10.7 percent decrease. Adjusted for exchange rate fluctuations, net sales decreased by 9.7 percent.
- Gross profit totaled SEK 45.8 million (56.8), corresponding to a gross margin of 76.0 percent (84.2).
- Operating profit (EBIT) amounted to SEK 0.5 million (5.5).
- Profit/loss after tax totaled SEK 1.6 million (1.3).
- Earnings per share before and after dilution amounted to SEK 0.10 (0.08).
- Cash flow from operating activities stood at SEK 12.3 million (2.6).

The period from January to June 2026

- Net sales amounted to SEK 122.0 million (122.2), corresponding to a 0.1 percent decrease. Adjusted for exchange rate fluctuations, net sales increased by 4.9 percent.
- Gross profit totaled SEK 96.2 million (102.4), corresponding to a gross margin of 78.9 percent (83.8).
- Operating profit (EBIT) amounted to SEK 3.1 million (-9.3).
- Profit/loss after tax totaled SEK 4.5 million (-19.3).
- Earnings per share before and after dilution amounted to SEK 0.27 (-1.16).
- Cash flow from operating activities stood at SEK 24.4 million (-3.0).

Important events during the quarter

Devyser completed its acquisition of CyberGene AB

On April 1, the acquisition of 100 percent of the shares in CyberGene AB was completed and closing took place. The acquisition strengthens Devyser's customer offering in the aneuploidy segment and is expected to have a positive impact on Devyser's gross profit and gross margin. At the time of closing, Devyser issued consideration shares to the seller, Level Bio AB (publ). See Note 6.

A strengthened management team - appointment of a new CFO

In May, Devyser announced that it had appointed Niklas Axelsson as its new CFO, effective no later than November 2026. Niklas has over 25 years of experience in the pharmaceutical, life sciences and financial sectors. Sabina Berlin will transition to a new role, with responsibility for Investor Relations and Corporate Compliance, when Niklas takes up his post.

Devyser won a SEK 8.9 million contract in Italy

In June, Devyser won a contract in the Basilicata Region of Italy, with a total value of SEK 8.9 million. The contract covers several of Devyser's main diagnostic products and is expected to significantly increase annual revenue, while further strengthening the company's position in Italy, which is one of its most important European markets.

Important events after the end of the quarter

Weaker sales in the second quarter due to a distributor's inventory buildup

Just after period end, Devyser announced that sales for the second quarter were weaker than expected. Sales were negatively impacted by the fact that the company's single largest distributor built up a large inventory in 2025 and early 2026, which reduced its need to make purchases during the period.

Sales growth in the Group's direct markets and other distributor markets remains positive.

Due to the distributor's inventory buildup, sales to this distributor are also expected to be lower for the remainder of 2026. Sales are expected to return to normal from 2027, and the company is confident about future development and growth.

The company believes that, despite weaker sales during the period, the Group's cash position and cash flow forecast are satisfactory.

Devyser launched One Lambda Devyser Chimerism Plus

In July, Devyser announced an expanded collaboration with Thermo Fisher Scientific through the launch of One Lambda Devyser Chimerism Plus, a next-generation solution for chimerism analysis following stem cell transplants. The launch strengthens Devyser's product portfolio, and the product will reach the market through Thermo Fisher's global network.

Performance measures	Apr - Jun 2026	Apr - Jun 2025	Jan - Jun 2026	Jan - Jun 2025	July 2025 - June 2026	Jan - Dec 2025
Net sales, SEK million	60.2	67.4	122.0	122.2	250.4	250.5
Sales growth, %	-10.7	26.6	-0.1	17.5	6.5	15.5
Gross margin, %	76.0	84.2	78.9	83.8	78.2	80.6
Operating profit/loss (EBIT), SEK million[1]	0.5	5.5	3.1	-9.3	22.4	10.1
Operating margin (EBIT margin), %[1]	0.8	8.1	2.5	Neg	9.0	4.0
Profit/loss after tax, SEK million	1.6	1.3	4.5	-19.3	15.3	-8.4
Cash flow from operating activities, SEK million[1]	12.3	2.6	24.4	-3.0	35.6	8.2
Cash and cash equivalents, SEK million	81.0	100.4	81.0	100.4	81.0	77.5
Equity ratio, %	77.3	73.3	77.3	73.3	77.3	75.4
Return on equity, %	0.4	0.4	1.2	Neg	4.3	Neg

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1.
See page 16 for definitions of the performance measures.

A word from the CEO

As previously announced, the second quarter was weaker than expected. Sales were negatively impacted by previous inventory build up by our single largest distributor. Underlying demand remains strong, and our direct sales markets and other distributor markets are continuing to grow. We are still standing by our positive long-term outlook, as the business model is delivering results, our collaboration with Thermo Fisher Scientific is stronger than ever, and our growth drivers are unchanged.

A temporary setback with continued strong demand

Net sales for the second quarter amounted to SEK 60.2 million. For the first half of the year, this translates to sales of SEK 122.0 million, in line with the previous year.

The quarter was negatively impacted by the fact that our largest distributor built up a larger inventory in 2025 and early 2026, which temporarily reduced its need to make purchases during this period. As a result of the inventory buildup, sales to the distributor are expected to be weaker for the rest of the year, before returning to normal in 2027. The decrease in sales is due to the distribution of purchases over time, rather than underlying demand, which is continuing to develop well. The growth in sales of our transplant products to end customers has been above our financial targets over the last 18 months, albeit starting from relatively small volumes, and we are confident about future growth.

In our key European markets, underlying demand remains generally stable, and the growth trend that we have seen since 2025 is expected to continue.

The gross margin for the quarter was 76.0 percent, compared with 84.2 percent for the same quarter of the previous year. The margin is lower primarily due to a one-off effect on inventory. Excluding this effect, the gross margin so far this year stands at 80 percent, in line with the level that Devyser has consistently delivered. The margin drivers are stable, and we expect the margin to increase as the company grows.

Operating profit/loss for the quarter remained positive, although significantly weaker than in the corresponding quarter of last year, amounting to SEK 0.5 million. Despite weaker sales, cash flow from operating activities is continuing to increase, and amounted to SEK 12.3 million, compared with SEK 2.6 million the previous year. We are closely monitoring cash flow and cost development, and it is clear that our long-term efforts in this area are producing the desired results.

In July, Devyser entered into a loan agreement with SEB, providing access to borrowing facilities of up to SEK 70 million. The loan is on market terms and gives us greater strategic flexibility as well as a buffer for unexpected events. The credit facility will not affect our focus on sustainable growth, and all decisions will continue to be made with both cash flow and EBIT in mind.

Deepened collaboration with Thermo Fisher Scientific

Our collaboration with Thermo Fisher Scientific works well. We received a visit from Thermo Fisher during the period, and we are currently working on several joint development projects. A specific example is the recently announced launch of One Lambda Devyser Chimerism Plus. This new solution for post-stem-cell-transplant monitoring strengthens our portfolio and will reach the market through Thermo Fisher's global network. We are continually developing a deeper partnership, and this launch clearly reflects the strong, long-term relationship that we have built together.

Acquisition and a stronger position in Italy

We completed our acquisition of CyberGene AB during the quarter, with a closing date of April 1. CyberGene's aneuploidy and male infertility products complement our existing product portfolio well, and the acquisition is expected to have a positive impact on both our gross profit and gross margin. In June, we were also awarded a five-year contract in the Basilicata Region of Italy worth SEK 8.9 million, which expects to increase revenue from the customer significantly. Italy is one of our most important European markets, and these agreements strengthens our position while providing good visibility over time.

Regulatory work is proceeding as planned

Our regulatory work is progressing. Both the FDA process and the MolDx application are moving forward according to plan, and we remain committed to our goal of announcing a decision on MolDx before the end of the year. At the same time, we are continuing to develop our clinical and regulatory evidence as we work towards our IVDR certifications.

> "The second quarter was weaker than expected, but this is a temporary setback against a backdrop of otherwise strong development."

Strengthening of the management team

During the quarter, our management team was strengthened by the appointment of Niklas Axelsson as our new CFO. Niklas has over 25 years of experience in the pharmaceutical, life sciences and financial sectors. He will take up his post in the second half of 2026. Sabina Berlin will then transition to a new role, with responsibility for Investor Relations and Corporate Compliance. Our former Chief Commercial Officer, Theis Kipling, has decided to leave the company to take up a new position, and I would like to thank him for his valuable contributions. The search for a successor has begun.

Outlook

The second quarter was weaker than expected, but this is a temporary setback against a backdrop of otherwise strong development. Demand remains strong; both our direct sales markets and our other distributor markets are growing, and we are developing a deeper collaboration with Thermo Fisher. We have further sharpened our focus on costs and are prioritizing our core business, continuing to concentrate on the US and Western Europe.

Devyser aims to be a company that consistently delivers profitable growth and continues to grow faster than the underlying market. Sales to our largest distributor are expected to return to normal from 2027, and we are confident that we will continue to grow.

I would like to extend my warmest thanks to all the company's employees, partners and shareholders. Your commitment and trust make our continued journey possible.

Stockholm, July 20, 2026

Jan Wahlström, CEO

Group development, January to June 2026

Net sales

Net sales for the period from January to June 2026 amounted to SEK 122.0 million (122.2), corresponding to a 0.1 percent decrease. Adjusted for exchange rate fluctuations, sales increased by 4.9 percent.

Net sales for the second quarter of 2026 amounted to SEK 60.2 million (67.4), corresponding to a 10.7 percent decrease. Adjusted for exchange rate fluctuations, the decrease was 9.7 percent.

The decrease during the second quarter is primarily related to lower sales to the company's largest supplier due to an large inventory buildup during previous periods, which is expected to continue to affect sales for the remainder of 2026. Sales growth in the Group's direct markets and other distributor markets remains positive.

There are no major seasonal variations in the company's sales.

Gross profit

Gross profit for the period from January to June 2026 totaled SEK 96.2 million (102.4). Gross profit for the second quarter totaled SEK 45.8 million (56.8).

The gross margin for the period from January to June 2026 amounted to 78.9 percent, compared with 83.8 percent for the same period of the previous year.

For the second quarter, the gross margin amounted to 76.0 percent, compared with 84.2 percent for the same quarter of last year. The gross margin for the quarter was negatively impacted by a one-off effect in inventory in the quarter.

Cost of goods sold includes the direct manufacturing costs of products sold and the amortization of capitalized development expenses.

The amortization of capitalized development expenses amounted to SEK 4.4 million (2.7) for the period from January to June, and to SEK 2.2 million (1.4) during the second quarter of 2026.

Operating expenses

Operating expenses for the period from January to June 2026 came to SEK 93.6 million (111.4), and for the second quarter to SEK 45.9 million (51.2). The decrease in expenses for the quarter is primarily due to a strong cost focus and a more effecient organization.

Total research and development expenses during the period from January to June 2026 amounted to SEK 37.3 million (54.5), of which SEK 25.7 million (42.4) was capitalized and SEK 11.6 million (12.1) was expensed. During the second quarter of 2026, total expenses amounted to SEK 19.5 million (22.5), of which SEK 13.2 million (17.4) was capitalized and SEK 6.3 million (5.0) was expensed.

The expensed research and development costs mainly comprise employee and consultant-related costs attributable to the R&D department's non-capitalizable project phases. The capitalized expenses include costs for development projects related to products not yet completed.

For the period from January to June 2026, other operating income and expenses, mainly consisting of exchange gains/losses on current assets and current liabilities, amounted to SEK 0.4 million (-0.4) net, and amounted to SEK 0.7 million (-0.1) net for the second quarter. See Note 1.

Operating profit/loss

Operating profit/loss for the period from January to June 2026 totaled SEK 3.1 million (-9.3). For the second quarter, operating profit/loss stood at SEK 0.5 million (5.5). See Note 1. The improvement in operating profit/loss for the first half of 2026 is primarily due to the cost-saving measures implemented, but it was also negatively impacted by lower net sales in the second quarter.

Net financial items

Net financial items for the period from January to June 2026 totaled SEK 2.9 million (-9.6). For the second quarter, net financial items amounted to SEK 1.1 million (-3.5). The net financial items consist mainly of currency translation differences related to long-term intra-Group loans in foreign currency. See Note 1.

Profit/loss

Profit/loss before tax for the period from January to June 2026 amounted to SEK 6.0 million (-18.9), and profit/loss after tax amounted to SEK 4.5 million (-19.3). For the second quarter, profit/loss before tax amounted to SEK 1.6 million (2.0), and after tax it amounted to SEK 1.6 million (1.3). Tax loss carryforwards are available for use. See Note 4.



Sales by region, SEK million	Apr - Jun 2026	Apr - Jun 2025	Change, %	Jan - Jun 2026	Jan - Jun 2025	Change, %	Jul 2025 - Jun 2026	Jan - Dec 2025
EMEA	52.7	51.3	2.7	101.0	97.1	4.1	213.4	209.4
Asia-Pacific	2.3	1.8	25.7	3.8	3.5	8.9	7.8	7.4
North and South America	5.2	14.3	-63.4	17.2	21.6	-20.6	29.2	33.6
Total	**60.2**	**67.4**	**-10.7**	**122.0**	**122.2**	**-0.1**	**250.4**	**250.5**

Sales by sales channel, SEK million	Apr - Jun 2026	Apr - Jun 2025	Change, %	Jan - Jun 2026	Jan - Jun 2025	Change, %	Jul 2025 - Jun 2026	Jan - Dec 2025
Direct sales	48.5	42.6	14.0	93.3	82.1	13.6	179.7	168.5
Distributor sales	11.7	24.9	-53.0	28.7	40.0	-28.3	70.7	82.0
Total	**60.2**	**67.4**	**-10.7**	**122.0**	**122.2**	**-0.1**	**250.4**	**250.5**

Cash flow and cash position

For the period from January to June 2026, cash flow from operating activities after changes in working capital totaled SEK 24.4 million (-3.0). For the second quarter of 2026, cash flow from operating activities totaled SEK 12.3 million (2.6). During the period, five new issues of a total of 236,149 shares were completed; one when CyberGene AB was acquired, and four in connection with the exercising of employee stock options issued to employees. The issues in connection with the exercising of employee stock options raised SEK 9.9 million for the company. Cash and cash equivalents as of June 30, 2026 amounted to SEK 81.0 million (100.4).

Investments

Total net investments during the period from January to June 2026 amounted to SEK 25.7 million (37.8), including capitalized development expenses of SEK 25.7 million (36.1). For the period from April to June, total net investments amounted to SEK 12.9 million (17.6), including capitalized development expenses of SEK 13.2 million (17.4) and a positive impact from the acquisition of Cybergene AB. The Group has no investment commitments.

Assets

As of June 30, 2026, intangible non-current assets amounted to SEK 191.4 million (133.3). Intangible non-current assets consist of capitalized development expenses for Devyser's products, other intangible assets and consolidated goodwill.

During the period from January to June 2026, SEK 20.6 million (26.9) of the capitalized development expenses was apportioned to the Research and Development function, SEK 3.8 million (9.0) to the Sales function, and SEK 1.3 million (0.3) to other functions. Capitalized development expenses is amortized on a straight-line basis over their estimated useful lives, which vary from four to ten years.

The amortization of capitalized development expenses attributable to the products developed by Devyser is recognized in the Group cost of goods sold and in the Parent Company's research and development costs.

Equity and liabilities

As of June 30, 2026, the Group's equity amounted to SEK 381.0 million (338.0), and its equity ratio was 77.3 percent (73.3).

As of June 30, 2026, interest-bearing liabilities amounted to SEK 45.7 million (54.2). Interest-bearing liabilities consist mainly of lease liabilities attributable to leases. Current non-interest-bearing liabilities totaled SEK 57.4 million (61.7).

Performance measures by quarter	Apr - Jun 2026	Jan - Mar 2026	Oct - Dec 2025	Jul - Sep 2025	Apr - Jun 2025	Jan - Mar 2025	Oct - Dec 2024
Net sales, SEK million	60.2	61.8	72.0	56.4	67.4	54.8	64.2
Gross profit, SEK million	45.8	50.5	57.2	42.3	56.8	45.6	54.2
Gross margin, %	76.0	81.6	79.5	75.0	84.2	83.4	84.4
EBITDA, SEK million[1]	8.1	10.1	25.0	8.1	12.2	-8.1	3.5
EBITDA margin, %[1]	13.4	16.3	34.7	14.4	18.1	Neg	5.5
Operating profit/loss (EBIT), SEK million[1]	0.5	2.6	18.0	1.3	5.5	-14.8	-3.7
Operating margin (EBIT margin), %[1]	0.8	4.2	25.1	2.3	8.1	Neg	Neg
Profit/loss after tax, SEK million	1.6	2.9	13.6	-2.8	1.3	-20.5	-3.2
Cash flow from operating activities, SEK million[1]	12.3	12.1	11.7	-0.5	2.6	-5.6	-5.9
Average no. of employees	110	110	110	108	114	120	121

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1.
See page 16 for definitions of the performance measures.

Parent Company

Devyser Diagnostics AB (publ), Corporate Registration Number 556669-7834, is a Swedish limited company domiciled in Stockholm. The address of its head office is Bränningevägen 12, 120 54 Årsta, Sweden. Devyser Diagnostics AB has been listed on the Nasdaq First North Premier Growth Market since December 2021.

Receivables and liabilities in respect of Group companies primarily consist of amounts owed by the Swedish subsidiary Devyser AB and the Italian subsidiary Devyser Italia S.r.l. The Parent Company's risks and uncertainties indirectly coincide with those of the Group.

Important events in the Parent Company

The improved result for the Parent Company compared with last year is mainly due to costs in 2025 related to the reorganization initiated in Q1 2025.

During the period from January to June 2026, five new issues of a total of 236,149 shares were completed; one when CyberGene AB was acquired, and four in connection with the exercising of employee stock options issued to employees. The issues in connection with the exercising of employee stock options raised SEK 9.9 million for the company.

Employees

From January to June 2026, the average number of Group employees was 110 (118), of which 2 (1) in the Parent Company. The average number broken down by country was 75 (80) in Sweden, 16 (16) in Italy, 6 (11) in the United States, 3 (3) in Germany, 3 (3) in Belgium, 2 (1) in the United Kingdom, 2 (2) in Spain and 2 (2) in France. The average number of women employed by the Group was 67 (68) and the average number of men was 43 (49).

Market

Devyser sells genetic testing products to laboratories in more than 65 countries. The products include reagent kits and the related software. Sales are made primarily to routine diagnostic laboratories, partly through our own sales teams in selected markets and partly through distributors.

The products are used for advanced DNA analysis services for clinical genetics and post-transplantation laboratories for the diagnosis of a wide range of genetic diseases and transplant patient follow-up.

The market size for the company's products is large and, according to an external market survey conducted in 2021, should reach EUR 5.6 billion by 2026.

Transactions with related parties

See Notes 2 and 3 for a description of the incentive programs and transactions with related parties.

Significant risks and uncertainties

The Group's activities are associated with a number of risks and uncertainties.

While Russia's invasion of Ukraine and the uncertain situation in the Middle East have no direct impact on Devyser, geopolitical uncertainty and the impact on global transportation may affect both the price of purchased goods and the company's ability to deliver to its customers.

The continued uncertainty regarding global trade barriers and the increased risk of a trade war could affect Devyser if its suppliers raise their prices. Tariffs on imports into the US are expected to have a limited impact on the company's costs and revenues.

A possible recession driven by the global turmoil could affect future revenues.

Devyser's sales are mainly in Euros and US dollars, meaning that the company is exposed to exchange rate fluctuations.

For more information, a detailed description of the company's risk exposure can be found in the 2025 Annual Report, pages 43-44, and in Note 13, pages 81-89. No changes are considered to have occurred since the Annual Report was published other than those described above.

The share and shareholders

As of June 30, 2026, Devyser Diagnostics AB had a total of 16,889,806 (16,592,560) shares and votes.

On the submission date of this report, the company had four outstanding incentive programs for employees and key personnel.

The existing and new incentive programs may currently increase the number of shares by 368,653 (see Note 2).

The largest shareholders as of June 30, 2026 were:

Owner	Number of shares	Ownership, %
Rutger Arnhult via company	4,065,382	24.1
Handelsbanken Fonder	1,018,649	6.0
Nordnet Pensionsförsäkringar	1,009,248	6.0
Premier Miton Investors	1,001,747	5.9
Deka Investments	946,178	5.6
Fourth Swedish National Pension Fund	759,821	4.5
Åsa Riisberg via company	664,294	3.9
Protean Funds Scandinavia	630,028	3.7
Swedbank Robur	570,000	3.4
Janus Henderson Investors	532,407	3.2
Other shareholders, around 1,900	5,692,052	33.7
Total	**16,889,806**	**100.0**

Source: Monitor

Auditors' review

This report has not been reviewed by the company's auditors.

The Board of Directors and CEO certify that the interim report provides a true and fair overview of the operations, financial position and earnings of the Group and the Parent Company and describes the significant risks and uncertainties faced by the Parent Company and the companies included in the Group.

Stockholm, July 20, 2026
Devyser Diagnostics AB (publ)

Mia Arnhult Chair of the Board	Fredrik Dahl Board member	Olof Ericsson Board member
Thomas Eklund Board member	Pia Gideon Board member	Jan Wahlström Chief Executive Officer

Consolidated income statement

SEK million	Apr - Jun 2026	Apr - Jun 2025	Jan - Jun 2026	Jan - Jun 2025	Jul 2025 - Jun 2026	Jan - Dec 2025
Net sales	60.2	67.4	122.0	122.2	250.4	250.5
Cost of goods sold	-14.4	-10.6	-25.8	-19.8	-54.6	-48.6
Gross profit	**45.8**	**56.8**	**96.2**	**102.4**	**195.7**	**201.9**
Other operating income[1]	0.9	-0.2	1.8	4.5	0.6	3.3
Selling expenses[2]	-26.4	-31.9	-54.7	-66.8	-105.2	-117.3
Administrative expenses	-13.3	-14.3	-27.2	-32.5	-50.7	-56.0
Research and development costs	-6.3	-5.0	-11.6	-12.1	-17.5	-18.0
Other operating expenses[1]	-0.3	0.1	-1.4	-4.8	-0.4	-3.9
Operating profit/loss[1]	**0.5**	**5.5**	**3.1**	**-9.3**	**22.4**	**10.1**
Financial income[1]	1.7	0.2	4.2	0.6	4.5	0.9
Financial expenses[1]	-0.7	-3.7	-1.3	-10.2	-4.7	-13.6
Net financial items[1]	1.1	-3.5	2.9	-9.6	-0.2	-12.7
Profit/loss before tax	**1.6**	**2.0**	**6.0**	**-18.9**	**22.2**	**-2.6**
Tax[3]	0.0	-0.7	-1.5	-0.4	-6.9	-5.8
Profit/loss for the period	**1.6**	**1.3**	**4.5**	**-19.3**	**15.3**	**-8.4**
Earnings per share before dilution, SEK	0.10	0.08	0.27	-1.16	0.92	-0.51
Diluted earnings per share, SEK	0.10	0.08	0.27	-1.16	0.92	-0.51
Average number of shares before dilution	16,802,100	16,554,536	16,729,977	16,554,326	16,679,786	16,592,683
Average number of shares after dilution	16,802,250	16,582,637	16,733,227	16,595,103	16,683,036	16,663,556

Consolidated statement of comprehensive income

SEK million	Apr - Jun 2026	Apr - Jun 2025	Jan - Jun 2026	Jan - Jun 2025	Jul 2025 - Jun 2026	Jan - Dec 2025
Profit/loss for the period	**1.6**	**1.3**	**4.5**	**-19.3**	**15.3**	**-8.4**
Other comprehensive income for the period:						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Items that will be reclassified to profit or loss						
Currency translation differences	-0.1	2.5	-0.5	3.0	-1.5	2.0
Other comprehensive income for the period	**-0.1**	**2.5**	**-0.5**	**3.0**	**-1.5**	**2.0**
Total comprehensive income for the period	**1.5**	**3.7**	**4.0**	**-16.3**	**13.9**	**-6.4**

Since there are no minority interests in the Group (no non-controlling interests), all earnings are wholly attributable to the owners of the Parent Company.

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1.
2) See Note 5.
3) See Note 4.

Consolidated statement of financial position

SEK million	June 30, 2026	June 30, 2025	Dec 31, 2025
ASSETS			
Non-current assets			
Goodwill	15.2	6.8	6.6
Capitalized development expenses	168.1	116.9	145.2
Other intangible assets	8.1	9.6	8.7
Equipment, tools and plant	29.1	33.6	30.8
Right-of-use assets	45.8	54.6	52.1
Deferred tax assets[1]	19.7	22.1	21.1
Other non-current receivables	1.0	1.0	1.0
Total non-current assets	**287.1**	**244.6**	**265.4**
Current assets			
Inventories	44.4	39.2	37.0
Trade receivables	60.1	53.4	56.8
Current tax assets	6.3	3.5	7.2
Other receivables	1.2	1.4	3.0
Prepaid expenses and accrued income	13.0	18.6	22.7
Cash and cash equivalents	81.0	100.4	77.5
Total current assets	**206.0**	**216.5**	**204.3**
TOTAL ASSETS	**493.1**	**461.1**	**469.7**
EQUITY AND LIABILITIES			
EQUITY			
Share capital	1.0	1.0	1.0
Share premium	567.6	540.0	545.7
Translation reserve	2.1	3.5	2.6
Retained earnings, including profit/loss for the period	-189.7	-206.5	-194.9
TOTAL EQUITY	**381.0**	**338.0**	**354.3**
LIABILITIES			
Non-current liabilities			
Borrowings	0.2	0.3	0.3
Lease liabilities	32.4	40.6	37.5
Deferred tax liabilities	0.0	0.1	0.1
Provisions[2]	6.6	5.4	4.6
Other non-current liabilities	2.4	1.7	2.0
Total non-current liabilities	**41.6**	**48.1**	**44.4**
Current liabilities			
Borrowings	-	0.1	-
Lease liabilities	13.2	13.2	14.1
Trade payables	18.1	7.1	17.9
Current tax liabilities	1.3	0.9	1.3
Other liabilities	12.4	10.4	15.1
Accrued expenses and deferred income	25.5	41.0	22.5
Provisions[2]	-	2.3	-
Total current liabilities	**70.6**	**75.0**	**70.9**
TOTAL EQUITY AND LIABILITIES	**493.1**	**461.1**	**469.7**

1) See Note 4.
2) See Note 5.

Consolidated statement of changes in equity

SEK million	Share capital	Share premium	Translation reserve	Retained earnings, including profit/loss for the period	Total equity
Opening equity, Jan 1, 2025	**1.0**	**536.5**	**0.6**	**-189.0**	**349.0**
Comprehensive income					
Profit/loss for the period	-	-	-	-19.3	-19.3
Other comprehensive income for the period	-	-	3.0	-	3.0
Total comprehensive income	-	-	3.0	-19.3	-16.3
Shareholder transactions					
New share issues	0.0	3.6	-	-	3.6
Issue expenses	-	-0.1	-	-	-0.1
Employee stock options	-	-	-	1.7	1.7
Closing equity, June 30, 2025	**1.0**	**540.0**	**3.5**	**-206.5**	**338.0**
Comprehensive income					
Profit/loss for the period	-	-	-	10.9	10.9
Other comprehensive income for the period	-	-	-1.0	-	-1.0
Total comprehensive income	-	-	-1.0	10.9	9.9
Shareholder transactions					
New share issues	0.0	5.8	-	-	5.8
Issue expenses	-	-0.0	-	-	-0.0
Employee stock options[1]	-	-	-	0.7	0.7
Closing equity, Dec 31, 2025	**1.0**	**545.7**	**2.6**	**-194.9**	**354.3**
Opening equity, Jan 1, 2026	1.0	545.7	2.6	-194.9	354.3
Comprehensive income					
Profit/loss for the period	-	-	-	4.5	4.5
Other comprehensive income for the period	-	-	-0.5	-	-0.5
Total comprehensive income	-	-	-0.5	4.5	4.0
Shareholder transactions					
New share issues	0.0	22.2	-	-	22.2
Issue expenses	-	-0.2	-	-	-0.2
Employee stock options[1]	-	-	-	0.7	0.7
Closing equity, June 30, 2026	**1.0**	**567.6**	**2.1**	**-189.7**	**381.0**

1) The item employee stock options includes net share-based payments and the related deferred tax.

Consolidated cash flow statement

SEK million	Apr - Jun 2026	Apr - Jun 2025	Jan - Jun 2026	Jan - Jun 2025	Jul 2025 - Jun 2026	Jan - Dec 2025
Cash flow from operating activities						
Operating profit/loss[1,2]	0.5	5.5	3.1	-9.3	22.4	10.1
Adjustment for non-cash items						
- Depreciation, amortization and impairment	7.5	6.7	15.0	13.3	28.8	27.1
- Other non-cash items	0.9	1.5	3.2	2.4	3.5	2.7
Interest received	0.1	0.0	0.1	0.0	1.0	0.9
Interest paid	-0.7	-1.3	-1.3	-1.6	-2.8	-3.0
Income tax paid	-0.8	-1.3	0.0	-0.9	-7.4	-8.4
Cash flow from operating activities before changes in working capital[1]	**7.6**	**11.1**	**20.1**	**3.9**	**45.5**	**29.3**
Cash flow from changes in working capital						
Increase (-)/Decrease (+) in inventories	-2.3	-3.4	-7.0	-9.4	-4.9	-7.3
Increase (-)/Decrease (+) in operating receivables	4.8	-6.1	11.2	-1.9	0.7	-12.5
Increase (+)/Decrease (-) in operating payables	2.3	1.0	0.0	4.3	-5.7	-1.4
Cash flow from operating activities[1]	**12.3**	**2.6**	**24.4**	**-3.0**	**35.6**	**8.2**
Cash flow from investing activities						
Investments in intangible non-current assets	-13.4	-17.5	-25.8	-36.6	-57.9	-68.7
Investments in property, plant and equipment	-1.0	-0.1	-1.3	-0.7	-2.2	-1.5
Aquisition of subsidiaries	1.4	-	1.4	-	1.4	-
Change in financial assets	-	0.0	-	-0.5	0.0	-0.5
Cash flow from investing activities	**-12.9**	**-17.6**	**-25.7**	**-37.8**	**-58.6**	**-70.7**
Cash flow from financing activities						
New share issues	9.0	3.6	9.9	3.6	15.7	9.4
Issue expenses	-0.2	-0.1	-0.2	-0.1	-0.3	-0.2
Repayments of borrowings	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1
Repayments of lease liabilities	-3.2	-3.0	-6.2	-5.8	-12.3	-12.0
Cash flow from financing activities	**5.6**	**0.5**	**3.5**	**-2.4**	**3.0**	**-2.8**
Cash flow for the period[1]	**5.0**	**-14.5**	**2.2**	**-43.2**	-19.9	-65.4
Cash and cash equivalents at the beginning of the period	75.3	114.1	77.5	144.5	100.4	144.5
Exchange gains/losses on cash and cash equivalents[1]	0.7	0.8	1.3	-0.9	0.6	-1.7
Cash and cash equivalents at the end of the period	**81.0**	**100.4**	**81.0**	**100.4**	**81.0**	**77.5**

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1.
2) See Note 5.

Parent Company income statement

SEK million	Apr - Jun 2026	Apr - Jun 2025	Jan - Jun 2026	Jan - Jun 2025	Jan - Dec 2025
Net sales	16.2	13.6	24.9	23.0	49.8
Cost of goods sold	-0.3	0.0	-0.3	-0.2	-0.4
Gross profit	**15.9**	**13.6**	**24.6**	**22.8**	**49.4**
Other operating income	0.0	0.0	0.0	0.0	0.0
Administrative expenses	-5.6	-6.0	-11.0	-15.5	-24.6
Research and development costs	-2.1	-1.4	-4.2	-2.6	-5.4
Other operating expenses	-0.0	-	-0.0	-0.0	-0.0
Operating profit/loss	**8.2**	**6.3**	**9.5**	**4.7**	**19.3**
Net interest and similar items	0.0	0.7	0.1	0.6	2.3
Profit/loss from financial items	**0.0**	**0.7**	**0.1**	**0.6**	**2.3**
Profit/loss after financial items	**8.3**	**7.0**	**9.6**	5.3	21.6
Appropriations	-	-	-	-	-32.6
Profit/loss before tax	**8.3**	**7.0**	**9.6**	**5.3**	**-10.9**
Tax[1]	-	0.1	-0.1	0.0	-1.3
Profit/loss for the period	**8.3**	**7.1**	**9.5**	**5.3**	**-12.2**

Parent Company statement of comprehensive income

SEK million	Apr - Jun 2026	Apr - Jun 2025	Jan - Jun 2026	Jan - Jun 2025	Jan - Dec 2025
Profit/loss for the period and Total comprehensive income for the period	**8.3**	**7.1**	**9.5**	**5.3**	**-12.2**

As there are no items of other comprehensive income, the Parent Company's earnings are the same as the comprehensive income.

1) See Note 4.

Parent Company balance sheet

SEK million	June 30, 2026	June 30, 2025	Dec 31, 2025
ASSETS			
Non-current assets			
Intangible assets			
Capitalized development expenses	132.6	99.7	119.0
Total intangible assets	**132.6**	**99.7**	**119.0**
Financial non-current assets			
Investments in Group companies	170.9	156.9	157.8
Deferred tax assets[1]	19.1	20.5	19.2
Total financial non-current assets	**190.0**	**177.4**	**177.0**
Total non-current assets	**322.6**	**277.1**	**296.0**
Current assets			
Amounts owed by Group companies	44.3	20.3	20.4
Current tax assets	0.8	0.8	0.5
Other receivables	0.0	-0.0	-
Prepaid expenses and accrued income	1.5	1.6	0.5
Cash in hand and at bank	15.0	63.7	33.7
Total current assets	**61.7**	**86.4**	**55.1**
TOTAL ASSETS	**384.3**	**363.4**	**351.1**
EQUITY AND LIABILITIES			
EQUITY			
Share capital	1.0	1.0	1.0
Statutory reserve	3.7	3.7	3.7
Reserve for development expenses	132.6	100.0	119.0
Total restricted equity	**137.3**	**104.7**	**123.7**
Share premium reserve	563.9	536.3	542.0
Retained earnings	-333.0	-290.1	-308.6
Profit/loss for the period	9.5	5.3	-12.2
Total non-restricted equity	**240.4**	**251.5**	**221.1**
TOTAL EQUITY	**377.8**	**356.1**	**344.9**
LIABILITIES			
Non-current liabilities			
Provisions	–	1.2	–
Total non-current liabilities	**-**	**1.2**	**-**
Current liabilities			
Trade payables	1.2	0.7	0.9
Amounts owed to Group companies	0.1	-	0.0
Other liabilities	3.2	-0.6	3.6
Accrued expenses and deferred income	2.1	6.0	1.7
Total current liabilities	**6.6**	**6.1**	**6.2**
TOTAL EQUITY AND LIABILITIES	**384.3**	**363.4**	**351.1**

1) See Note 4.

Changes in the Parent Company's equity

SEK million	Share capital	Reserve for development expenses	Reserves	Share premium reserve	Retained earnings	Profit/loss for the period	Total equity
Opening equity, Jan 1, 2025	**1.0**	**70.8**	**3.7**	**532.7**	**-206.2**	**-56.3**	**345.7**
Profit/loss for the period	-	-	-	-	-	5.3	5.3
Appropriation of earnings	-	-	-	-	-56.3	56.3	-
Capitalization of development expenses	-	29.2	-	-	-29.2	-	-
New share issues	0.0	-	-	3.6	-	-	3.6
Issue expenses	-	-	-	-0.1	-	-	-0.1
Employee stock options	-	-	-	-	1.6	-	1.6
Closing equity, June 30, 2025	**1.0**	**100.0**	**3.7**	**536.3**	**-290.1**	**5.3**	**356.1**
Profit/loss for the period	-	-	-	-	-	-17.5	-17.5
Capitalization of development expenses	-	19.1	-	-	-19.1	-	-
New share issues	0.0	-	-	5.8	-	-	5.8
Issue expenses	-	-	-	-0.0	-	-	-0.0
Employee stock options	-	-	-	-	0.5	-	0.5
Closing equity, Dec 31, 2025	**1.0**	**119.0**	**3.7**	**542.0**	**-308.6**	**-12.2**	**344.9**
Opening equity, Jan 1, 2026	**1.0**	**119.0**	**3.7**	**542.0**	**-308.6**	**-12.2**	**344.9**
Profit/loss for the period	-	-	-	-	-	9.5	9.5
Appropriation of earnings	-	-	-	-	-12.2	12.2	-
Capitalization of development expenses	-	13.6	-	-	-13.6	-	-
New share issues	0.0	-	-	22.2	-	-	22.2
Issue expenses	-	-	-	-0.2	-	-	-0.2
Employee stock options[1]	-	-	-	-	1.4	-	1.4
Closing equity, June 30, 2026	**1.0**	**132.6**	**3.7**	**563.9**	**-333.0**	**9.5**	**377.8**

1) The item employee stock options includes net share-based payments and the related deferred tax.

Parent Company cash flow

SEK million	Apr - Jun 2026	Apr - Jun 2025	Jan - Jun 2026	Jan - Jun 2025	Jan - Dec 2025
Cash flow from operating activities					
Operating profit/loss	8.2	6.3	9.5	4.7	19.3
Adjustments for non-cash items					
- Depreciation, amortization and impairment	2.1	1.4	4.2	2.6	5.4
- Other non-cash items	0.3	0.9	0.6	0.6	2.1
Interest received	0.0	0.0	0.0	0.0	0.8
Interest paid	-0.0	-0.0	-0.0	-0.0	-0.0
Tax paid	-0.1	-0.1	-0.3	-0.3	-
Cash flow from operating activities before changes in working capital	**10.5**	**8.4**	**13.9**	**7.6**	**27.7**
Cash flow from changes in working capital					
Increase (-)/Decrease (+) in operating receivables	-32.5	-15.4	-36.5	-18.8	-51.0
Increase (+)/Decrease (-) in operating payables	11.5	-1.2	11.9	-9.8	-11.3
Cash flow from operating activities	**-10.5**	**-8.1**	**-10.6**	**-21.0**	**-34.5**
Cash flow from investing activities					
Investments in intangible non-current assets	-8.7	-12.6	-17.8	-31.8	-54.0
Cash flow from investing activities	**-8.7**	**-12.6**	**-17.8**	**-31.8**	**-54.0**
Cash flow from financing activities					
New share issues	9.0	3.6	9.9	3.6	9.4
Issue expenses	-0.2	-0.1	-0.2	-0.1	-0.2
Cash flow from financing activities	**8.8**	**3.5**	**9.7**	**3.5**	**9.2**
Cash flow for the period	**-10.3**	**-17.2**	**-18.7**	**-49.3**	**-79.3**
Cash and cash equivalents at the beginning of the period	25.3	80.8	33.7	113.0	113.0
Cash and cash equivalents at the end of the period	**15.0**	**63.7**	**15.0**	**63.7**	**33.7**

Notes

Note 1 Accounting policies

The interim report for the Devyser Group has been prepared in accordance with IFRS (International Financial Reporting Standards) as adopted by the EU. The Swedish Annual Accounts Act and RFR 1, Supplementary Accounting Rules for Groups, have also been applied.

The interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting. The Parent Company applies the Swedish Annual Accounts Act and RFR 2, Accounting for Legal Entities. Under RFR 2, the Parent Company is required to apply the same accounting policies as the Group, which means that IFRS should be applied as far as possible within the framework of the Swedish Annual Accounts Act, the Swedish Pension Obligations Protection Act and tax considerations.

New or amended IFRS standards and other IFRIC interpretations came into effect on January 1, 2026. None of the new standards had any impact on the Group's or Parent Company's financial statements at June 30, 2026.

All amounts are reported in millions of kronor (SEK million) unless otherwise stated. Figures in brackets refer to the previous year. The figures in tables and calculations may be rounded, meaning that the total amounts shown may not always be the exact sum of the rounded amounts.

For more information about the accounting policies, refer to the 2025 Annual Report.

Reclassification of currency translation differences related to long-term intra-Group loans

From April 1, 2025, Devyser will classify currency translation differences related to long-term intra-Group loans denominated in foreign currencies as financial income/expenses. These items were previously reported under other operating income/expenses. The aim is to ensure a more accurate presentation of the operating profit/loss and to better reflect the nature of the currency translation differences. Comparative figures have been restated. See the tables on page 15.

Segment reporting

Devyser applies IFRS 8 Operating segments. Devyser's activities are currently focused on development and sales within a niche and uniform category of goods of a similar nature in the product area of diagnostic reagents, and only one segment is therefore reported, which is fully reflected in the Group's financial statements. All of its development activities are centered on the same common base product. The Group's strategic steering committee and highest decision-makers, consisting of the CEO and a number of other senior executives who together form the senior management, evaluate the Group's activities as a whole based on products and product development. Sales are monitored by geographic region, currently Europe, the Middle East and Africa (EMEA), Asia-Pacific, North and South America and other regions. Refer to the table on page 4.

Note 2 Incentive programs

Devyser has four outstanding incentive programs for employees and key personnel.

2023/2027 employee stock option plan

The total plan comprises 200,000 employee stock options, plus 62,840 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 101.71 per share until June 2027. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of June 30, 2026, a total of 80,268 options had been granted and not exercised. Three members of the senior management together hold a total of 70,000 employee stock options.

2024/2028 employee stock option plan

The total plan comprises 200,000 employee stock options, plus 62,840 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 136.48 per share until June 2028. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of June 30, 2026, a total of 127,085 options had been granted and not exercised. Five members of the senior management together hold a total of 83,000 employee stock options.

2025/2029 employee stock option plan

The total plan comprises 200,000 employee stock options, plus 62,840 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 186.24 per share until September 2029. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of June 30, 2026, a total of 161,300 options had been granted and not exercised. CEO Jan Wahlström holds 60,000 options. Five members of the senior management together hold a total of 50,000 employee stock options.

Long-term performance-based compensation plan 2026/2029

At the Annual General Meeting in May, a resolution was passed to introduce a new long-term performance-based compensation plan. The total plan comprises 75,000 warrants, plus 23,565 options for the hedging of social security contributions. The options will be granted as stock options free of charge and vest over a period of 3 years from the grant date, following a performance review, provided that the holder remains an employee. The performance conditions will have three components: the meeting of sales growth targets, the meeting of profitability targets, and the meeting of the target number of tests administered to patients, during the fiscal years 2026, 2027, and 2028, and will be evaluated annually by the Board of Directors. Shares will be granted in 2029 after the end of the vesting period, provided that the conditions have been met.

As of June 30, 2026, a total of 0 stock options had been granted and not exercised.

Note 3 Related-party transactions

Related-party transactions arise in the normal course of business and are carried out at arm's length and market prices. No transactions with related parties took place during the period other than customary transactions between Group companies and the remuneration of management and the Board.

See Note 2 on incentive programs.

Note 4 Deferred tax

Within the Group, deferred tax is mainly recognized for accumulated losses, leases and share-based payments for which there are temporary differences that are grounds for the recognition of deferred tax.

The tax effects of loss carryforwards are taken into account only to the extent that there are convincing factors that suggest that these may be utilized in the foreseeable future. There are no time limits on any of the losses.

At year-end 2025, the Parent Company had unused tax loss carryforwards of SEK 254.5 million (241.0), corresponding to deferred tax assets of SEK 52.4 million (49.6). After valuation, SEK 19.1 million (19.1) are recognized in deferred tax assets in the balance sheet.

Note 5 Provision due to retroactive payback levy

The total provision recognized for the Italian Ministry of Health in connection with the payback levy for the years 2019-2025 amounted to SEK 4.6 million as of December 31, 2025. In the first and second quarters of 2026, an additional SEK 1.8 million (0.4) was recognized. For detailed information about the provision, see Note 20 on page 92 of the 2025 Annual Report.

Note 6 Acquisition of CyberGene AB

On 11 February 2026, Devyser entered into an agreement to acquire 100 percent of the shares in CyberGene AB, a Swedish company belonging to Level Bio AB (publ) Group. On April 1, 2026, the acquisition was completed and closing took place. The acquisition will strengthen Devyser's customer offering in the aneuploidy segment and is expected to have a positive impact on Devyser's gross profit and gross margin.

At the time of closing, new consideration shares were issued to the seller, Level Bio AB (publ). The acquisition price was SEK 12.2 million. The directed share issue consisted of 124,363 shares, corresponding to a dilutive effect of 0.74 percent. The subscription price amounted to SEK 98.29 per share.

CyberGene AB, corp. reg. No 556504-5019, will be consolidated from April 1, 2026. The fair value of the net assets acquired totals SEK 3.7 million, and the calculated goodwill totals SEK 8.5 million. The cash acquired amounts to SEK 1.4 million. CygerGene AB's sales in 2025 amounted to SEK 5.3 million, with a reported EBIT of SEK 1.3 million. CyberGene AB develops and markets products in the aneuploidy and male infertility fields.

Reclassification of currency translation differences related to long-term intra-Group loans

SEK million	Apr - Jun 2025 Recognized before reclassification	Apr - Jun 2025 Restated amount	Apr - Jun 2025 Recognized after reclassification	Jan - Mar 2025 Recognized before reclassification	Jan - Mar 2025 Restated amount	Jan - Mar 2025 Recognized after reclassification
Consolidated income statement						
Operating profit/loss	5.5	-	5.5	-20.5	5.7	-14.8
Net financial items	-3.5	-	-3.5	-0.4	-5.7	-6.1
Consolidated cash flow statement						
Operating profit/loss	5.5	-	5.5	-20.5	5.7	-14.8
Cash flow from operating activities before changes in working capital	10.8	0.3	11.1	-12.9	5.7	-7.2
Cash flow from operating activities	2.3	0.3	2.6	-11.4	5.7	-5.6
Cash flow for the period	-14.8	0.3	-14.5	-34.4	5.7	-28.7
Exchange gains/losses on cash and cash equivalents	1.1	-0.3	0.8	4.0	-5.7	-1.7

SEK million	Oct - Dec 2024 Recognized before reclassification	Oct - Dec 2024 Restated amount	Oct - Dec 2024 Recognized after reclassification
Consolidated income statement			
Operating profit/loss	0.7	-4.4	-3.7
Net financial items	-1.2	4.4	3.2
Consolidated cash flow statement			
Operating profit/loss	0.7	-4.4	-3.7
Cash flow from operating activities before changes in working capital	16.2	-4.5	11.7
Cash flow from operating activities	-1.4	-4.5	-5.9
Cash flow for the period	-23.0	-4.5	-27.5
Exchange gains/losses on cash and cash equivalents	-3.8	4.5	0.7

Use of non-IFRS performance measures

The Devyser Group prepares its consolidated financial statements in accordance with IFRS. Only a few performance measures are defined in the IFRS standards. Devyser applies the Guidelines on Alternative Performance Measures (APMs) issued by the European Securities and Markets Authority (ESMA). To support the assessment of the Group's performance made by senior management and other stakeholders, Devyser uses some non-IFRS performance measures. Senior management believes that these measures make it easier to evaluate the performance of the Group.

Definitions of non-IFRS performance measures that are not provided elsewhere in this report are presented in the following table. The measures have been calculated using the actual financial statements, including IFRS 16.

	Apr - Jun 2026	Apr - Jun 2025	Jan - Jun 2026	Jan - Jun 2025	Jul 2025 - Jun 2026	Jan - Dec 2025
Gross margin (gross profit/net sales)						
Gross profit, SEK million	45.8	56.8	96.2	102.4	195.7	201.9
Net sales, SEK million	60.2	67.4	122.0	122.2	250.4	250.5
Gross margin, %	76.0	84.2	78.9	83.8	78.2	80.6
EBITDA margin (EBITDA/net sales)						
Operating profit/loss, SEK million[1]	0.5	5.5	3.1	-9.3	22.4	10.1
Depreciation/amortization, SEK million	-7.5	-6.7	-15.0	-13.3	-28.8	-27.1
Net sales, SEK million	60.2	67.4	122.0	122.2	250.4	250.5
EBITDA margin, %[1]	13.4	18.1	14.9	3.3	20.5	14.8
Operating margin (operating profit/net sales)						
Operating profit/loss, SEK million[1]	0.5	5.5	3.1	-9.3	22.4	10.1
Net sales, SEK million	60.2	67.4	122.0	122.2	250.4	250.5
Operating margin, %[1]	0.8	8.1	2.5	Neg	9.0	4.0
Return on equity (profit for the period/average equity)						
Profit/loss for the period, SEK million	1.6	1.3	4.5	-19.3	15.3	-8.4
Average equity, SEK million	369.4	334.2	367.6	343.5	359.5	351.7
Return on equity, %	0.4	0.4	1.2	Neg	4.3	Neg
Equity ratio (closing equity for the period/closing total assets for the period)						
Closing equity, SEK million	381.0	338.0	381.0	338.0	381.0	354.3
Closing total assets, SEK million	493.1	461.1	493.1	461.1	493.1	469.7
Equity ratio, %	77.3	73.3	77.3	73.3	77.3	75.4
Growth adjusted for exchange rate changes (((sales in currency for the period * (previous period's average exchange rate - average exchange rate for the period in currency) + net sales)) - previous period's net sales)))/previous period's net sales)						
Net sales in EUR million	4.3	3.7	8.4	7.4	16.4	15.4
Net sales in USD million	1.1	1.8	3.6	2.5	6.3	5.2
Net sales in GBP million	0.1	0.2	0.2	0.3	0.5	0.6
Net sales, SEK million	60.2	67.4	122.0	122.2	250.4	250.5
Average exchange rate EUR/SEK	10.8902	10.9630	10.7944	11.1035	10.9170	11.0698
Average exchange rate USD/SEK	9.3696	9.6664	9.2561	10.1830	9.3597	9.8199
Average exchange rate GBP/SEK	12.5689	12.9065	12.4437	13.1829	12.5599	12.9258
Sales growth adjusted for exchange rate changes, %	Neg	34.1	4.9	20.7	12.1	20.2

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1.

About Devyser

Devyser is redefining how laboratories approach genetic testing. We offer streamlined and user-friendly solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta. and maintain sales offices across Europe and the US.

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR).

For more information, visit www.devyser.com.

Contact details

Sabina Berlin
CFO
Tel: +46 8 562 158 50
Email: ir@devyser.com

All reports are published on the company's website: https://investors.devyser.com/en/reports-presentations

Financial calendar

Interim report Q1 2026	April 27, 2026
Annual General Meeting 2026	May 6, 2026
Interim report Q2 2026	July 20, 2026
Interim report Q3 2026	November 3, 2026
Year-end report 2026	February 16, 2027

Analysts covering the Company

Arvid Necander, DNB Carnegie Investment Bank
Filip Wiberg, Pareto Securities

Devyser Diagnostics AB
Bränningevägen 12
120 54 Årsta, Sweden
www.devyser.com